All categories
Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Wellness category
Fat loss Peptides
Metabolic, lipolytic, and incretin-pathway peptides.
All 14 Fat loss peptides
Fat loss
AOD-9604
Modified GH fragment researched for adipose tissue effects.
Metabolic
5-Amino-1MQ
Small-molecule NNMT inhibitor researched for fat metabolism.
Weight loss
Retatrutide
Triple GLP-1/GIP/glucagon agonist in late-stage obesity trials.
Weight loss
Semaglutide
FDA-approved GLP-1 agonist for diabetes and obesity.
Weight loss
Tirzepatide
FDA-approved GLP-1/GIP dual agonist.
Weight loss
Cagrilintide
Long-acting amylin analog studied alongside GLP-1 agonists.
Weight loss
Survodutide
GLP-1/glucagon dual agonist in late-stage obesity trials.
Weight loss · Diabetes
Liraglutide
FDA-approved daily GLP-1 receptor agonist.
Metabolic
Tiragratide
Investigational triple hormone receptor agonist for metabolic disease.
Weight loss
Mazdutide
GLP-1/glucagon dual agonist in Phase 3 development.
FDA-Approved · Metabolic
Exenatide (Byetta / Bydureon)
First-in-class GLP-1 receptor agonist for type 2 diabetes.
FDA-Approved · Metabolic
Dulaglutide (Trulicity)
Once-weekly GLP-1 agonist with cardiovascular benefit.
FDA-Approved · Metabolic
Lixisenatide (Adlyxin)
Short-acting GLP-1 agonist focused on postprandial glucose.
FDA-Approved · Metabolic
Pramlintide (Symlin)
Amylin analog adjunct to mealtime insulin.